Spyre Therapeutics, Inc. - 10-Q Filing
Spyre Therapeutics reports Q3 2026 financial results including updates on preferred stock and subsequent equity offerings.
Tickers: $SYRE
Spyre Therapeutics reports Q3 2026 financial results including updates on preferred stock and subsequent equity offerings.
Tickers: $SYRE